Patent ID: RE41393

Claim:
A method for treating a tumor in a mammal, said tumor having demonstrated resistance to oncology therapy, comprising administering to said mammal an effective amount of a composition comprising a pharmaceutically acceptable carrier and an epothilone compound of formula: wherein: Q is selected from the group consisting of G is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, W is O or NR 15 ; X is O or H, H; Y is selected from the group consisting of O; H, OR 16 ; OR 17 , OR 17 ; NOR 18 ; H, NHOR 19 ; H, NR 20 R 21 ; H, H; and CHR 22 ; wherein OR 17 , OR 17 can be a cyclic ketal; each Z 1 and Z 2 is, independently, selected from the group consisting of CH 2 , O, NR 23 , S, and SO 2 , wherein only one of Z 1 and Z 2 can be a heteroatom; each B 1 and B 2 is, independently, selected from the group consisting of OR 24 , OCOR 25 , and O—C(═O)— NR 26 R 27 , and when B 1 is H and Y is OH, H, they can form a six-membered ring ketal or acetal; D is selected from the group consisting of NR 28 R 29 , NR 30 COR 31 and saturated heterocycle; each R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 18 , R 19 , R 20 , R 21 , R 22 , R 26 and R 27 is, independently, selected from the group consisting of H, alkyl, substituted alkyl, and aryl, and when R 1 and R 2 are alkyl can be joined to form a cycloalkyl, and when R 3 and R 4 are alkyl can be joined to form a cycloalkyl; each R 9 , R 10 , R 16 , R 17 , R 24 , R 25 and R 31 is, independently, selected from the group consisting of H, alkyl, and substituted alkyl; each R 8 , R 11 , R 12 , R 28 , R 30 , R 32 , and R 33 is, independently, selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl and heterocyclo; and each R 15 , R 23 and R 29 is, independently, selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R 32 C═O, R 33 SO 2 , hydroxy, O-alkyl or O-substituted alkyl; and pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein W and X are both O; R 1 , R 2 and R 7 are H; R 3 R 4 and R 6 are methyl; R 8 is H or methyl; Z 1 and Z 2 are CH 2 ; G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above, are excluded.